You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmprenavir
Accession NumberDB00701  (APRD00605)
TypeSmall Molecule
GroupsApproved
DescriptionAmprenavir is a protease inhibitor used to treat HIV infection.
Structure
Thumb
Synonyms
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate
Agenerase
Amprenavir
Amprénavir
Amprenavirum
External Identifiers
  • 141 W 94
  • KVX 478
  • VX-478
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AgeneraseCapsule50 mgOralGlaxosmithkline Inc2001-03-212008-05-27Canada
AgeneraseCapsule150 mgOralGlaxosmithkline Inc2001-03-162008-05-27Canada
AgeneraseLiquid15 mgOralGlaxosmithkline Inc2001-03-262008-05-27Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AgeneraseCapsule50 mgOralGlaxo Group Ltd.2000-10-20Not applicableEu
AgeneraseCapsule150 mgOralGlaxo Group Ltd.2000-10-20Not applicableEu
AgeneraseCapsule150 mgOralGlaxo Group Ltd.2000-10-20Not applicableEu
AgeneraseSolution15 mg/mlOralGlaxo Group Ltd.2000-10-20Not applicableEu
International Brands
NameCompany
AgemeraseGlaxoSmithKline
ProzeiKissei Pharmaceuticals Co., Ltd.
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5S0W860XNR
CAS number161814-49-9
WeightAverage: 505.627
Monoisotopic: 505.224656557
Chemical FormulaC25H35N3O6S
InChI KeyYMARZQAQMVYCKC-OEMFJLHTSA-N
InChI
InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
IUPAC Name
(3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate
SMILES
CC(C)CN(C[C@@H](O)[[email protected]](CC1=CC=CC=C1)NC(=O)O[[email protected]]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1
Pharmacology
IndicationFor the treatment of HIV-1 infection in combination with other antiretroviral agents.
Structured Indications Not Available
PharmacodynamicsAmprenavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Amprenavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism of actionAmprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
TargetKindPharmacological actionActionsOrganismUniProt ID
Pol polyproteinProteinyes
inhibitor
Human immunodeficiency virus 1Q72874 details
Related Articles
AbsorptionRapidly absorbed after oral administration in HIV-1-infected patients with a time to peak concentration (Tmax) typically between 1 and 2 hours after a single oral dose. The absolute oral bioavailability of amprenavir in humans has not been established.
Volume of distributionNot Available
Protein bindingVery high (90%). Amprenavir has the highest affinity for alpha(1)-acid glycoprotein.
Metabolism

Hepatic. Amprenavir is metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system. The 2 major metabolites result from oxidation of the tetrahydrofuran and aniline moieties. Glucuronide conjugates of oxidized metabolites have been identified as minor metabolites in urine and feces.

Route of eliminationNot Available
Half life7.1-10.6 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Amprenavir.Approved, Investigational
AbirateroneThe serum concentration of Amprenavir can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Amprenavir.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Amprenavir.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Amprenavir.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Amprenavir.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Amprenavir.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Amprenavir.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Amprenavir.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Amprenavir.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Amprenavir.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Amprenavir.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Amprenavir.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Amprenavir.Approved
AmiodaroneThe metabolism of Amprenavir can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Amprenavir.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Amprenavir.Approved
AprepitantThe serum concentration of Amprenavir can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Amprenavir.Approved, Investigational
ArtemetherThe metabolism of Amprenavir can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Amprenavir can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Amprenavir.Approved
AtomoxetineThe metabolism of Amprenavir can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Amprenavir.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Amprenavir.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Amprenavir.Investigational
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Amprenavir.Approved, Vet Approved
BetaxololThe metabolism of Amprenavir can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Amprenavir can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Amprenavir can be decreased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Amprenavir can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Amprenavir can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amprenavir.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Amprenavir.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Amprenavir.Approved, Investigational
BupropionThe metabolism of Amprenavir can be decreased when combined with Bupropion.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Amprenavir.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Amprenavir.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Amprenavir.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Amprenavir.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Amprenavir.Approved
CapecitabineThe metabolism of Amprenavir can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Amprenavir can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Amprenavir.Approved
CelecoxibThe metabolism of Amprenavir can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Amprenavir can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Amprenavir.Withdrawn
ChloroquineThe metabolism of Amprenavir can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Amprenavir.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Amprenavir.Approved, Vet Approved
CholecalciferolThe metabolism of Amprenavir can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Amprenavir.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Amprenavir.Approved
CinacalcetThe metabolism of Amprenavir can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Amprenavir.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Amprenavir.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Amprenavir.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Amprenavir.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Amprenavir.Approved
ClemastineThe metabolism of Amprenavir can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Amprenavir.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Amprenavir.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Amprenavir.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Amprenavir.Approved
ClopidogrelThe metabolism of Amprenavir can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Amprenavir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Amprenavir.Approved
CobicistatThe serum concentration of Amprenavir can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Amprenavir.Approved
CocaineThe metabolism of Amprenavir can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amprenavir.Approved
ConivaptanThe serum concentration of Amprenavir can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Amprenavir.Approved
CrizotinibThe metabolism of Amprenavir can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Amprenavir.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Amprenavir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Amprenavir.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Amprenavir can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Amprenavir.Approved
DabrafenibThe serum concentration of Amprenavir can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Amprenavir.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Amprenavir.Approved
DarifenacinThe metabolism of Amprenavir can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Amprenavir can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Amprenavir can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Amprenavir.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Amprenavir.Approved
DeferasiroxThe serum concentration of Amprenavir can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Amprenavir.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Amprenavir.Approved
DexamethasoneThe serum concentration of Amprenavir can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Amprenavir.Approved, Illicit, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Amprenavir.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amprenavir.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Amprenavir.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Amprenavir.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Amprenavir.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Amprenavir.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Amprenavir.Approved
DiphenhydramineThe metabolism of Amprenavir can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Amprenavir.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Amprenavir.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Amprenavir.Approved, Investigational, Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Amprenavir.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Amprenavir.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amprenavir.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Amprenavir.Approved, Investigational
DoxycyclineThe metabolism of Amprenavir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Amprenavir can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Amprenavir can be decreased when combined with Duloxetine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Amprenavir.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amprenavir.Approved
EfavirenzThe serum concentration of Amprenavir can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Amprenavir.Approved, Investigational
EliglustatThe metabolism of Amprenavir can be decreased when combined with Eliglustat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Amprenavir.Approved, Investigational
EnzalutamideThe serum concentration of Amprenavir can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Amprenavir.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Amprenavir.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Amprenavir.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Amprenavir.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Amprenavir.Approved, Investigational
ErythromycinThe metabolism of Amprenavir can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Amprenavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Amprenavir.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Amprenavir.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Amprenavir.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Amprenavir.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Amprenavir.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Amprenavir.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Amprenavir.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Amprenavir.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Amprenavir.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Amprenavir.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amprenavir.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Amprenavir.Approved
FelodipineThe metabolism of Amprenavir can be decreased when combined with Felodipine.Approved, Investigational
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Amprenavir.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Amprenavir.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Amprenavir.Approved
FloxuridineThe metabolism of Amprenavir can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Amprenavir can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Amprenavir can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Amprenavir can be decreased when combined with Fluoxetine.Approved, Vet Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Amprenavir.Approved
FluvastatinThe metabolism of Amprenavir can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Amprenavir can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Amprenavir can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amprenavir can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Amprenavir can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Amprenavir can be increased when it is combined with Fusidic Acid.Approved
GarlicThe serum concentration of Amprenavir can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Amprenavir.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Amprenavir.Approved
GemfibrozilThe metabolism of Amprenavir can be decreased when combined with Gemfibrozil.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Amprenavir.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Amprenavir.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Amprenavir.Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Amprenavir.Withdrawn
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Amprenavir.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Amprenavir.Approved
IdelalisibThe serum concentration of Amprenavir can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Amprenavir can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Amprenavir.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Amprenavir.Approved
IndinavirThe metabolism of Amprenavir can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Amprenavir.Approved, Investigational
IrbesartanThe metabolism of Amprenavir can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Amprenavir.Approved, Investigational
IsavuconazoniumThe metabolism of Amprenavir can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Amprenavir can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Amprenavir can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Amprenavir can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Amprenavir can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Amprenavir.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Amprenavir.Approved
KetoconazoleThe metabolism of Amprenavir can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Amprenavir.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Amprenavir.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Amprenavir.Approved, Investigational
LapatinibThe metabolism of Amprenavir can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Amprenavir.Approved
LeflunomideThe metabolism of Amprenavir can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Amprenavir.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Amprenavir.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Amprenavir.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Amprenavir.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Amprenavir.Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Amprenavir.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Amprenavir.Approved
LopinavirThe metabolism of Amprenavir can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Amprenavir can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Amprenavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Amprenavir.Approved, Investigational
LuliconazoleThe serum concentration of Amprenavir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Amprenavir can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Amprenavir can be decreased when combined with Lumefantrine.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Amprenavir.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Amprenavir.Approved
MethadoneThe metabolism of Amprenavir can be decreased when combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Amprenavir.Experimental
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Amprenavir.Approved
MethotrimeprazineThe metabolism of Amprenavir can be decreased when combined with Methotrimeprazine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Amprenavir.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Amprenavir.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Amprenavir.Approved, Illicit
MifepristoneThe serum concentration of Amprenavir can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Amprenavir.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Amprenavir.Approved
MitotaneThe serum concentration of Amprenavir can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Amprenavir.Approved, Investigational
ModafinilThe serum concentration of Amprenavir can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Amprenavir.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Amprenavir.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Amprenavir.Approved
NafcillinThe serum concentration of Amprenavir can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amprenavir.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Amprenavir.Approved, Vet Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Amprenavir.Approved, Withdrawn
NelfinavirThe metabolism of Amprenavir can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Amprenavir can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Amprenavir can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Amprenavir can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Amprenavir.Approved
NilotinibThe metabolism of Amprenavir can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amprenavir.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Amprenavir.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Amprenavir.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Amprenavir.Approved, Investigational
OlaparibThe metabolism of Amprenavir can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Amprenavir.Approved
OmeprazoleThe metabolism of Amprenavir can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Amprenavir.Investigational
OsimertinibThe serum concentration of Amprenavir can be increased when it is combined with Osimertinib.Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Amprenavir.Approved, Vet Approved
PalbociclibThe serum concentration of Amprenavir can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Amprenavir can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Amprenavir can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amprenavir.Approved
Peginterferon alfa-2bThe serum concentration of Amprenavir can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Amprenavir can be increased when combined with Pentobarbital.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Amprenavir is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Amprenavir can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Amprenavir can be increased when combined with Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Amprenavir.Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Amprenavir.Approved
PioglitazoneThe metabolism of Amprenavir can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Amprenavir.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Amprenavir.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Amprenavir.Approved
PosaconazoleThe metabolism of Amprenavir can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Amprenavir.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Amprenavir.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Amprenavir.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Amprenavir.Approved, Vet Approved
PrimidoneThe metabolism of Amprenavir can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Amprenavir.Approved, Vet Approved
PromazineThe metabolism of Amprenavir can be decreased when combined with Promazine.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Amprenavir.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Amprenavir.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amprenavir.Approved
PyrimethamineThe metabolism of Amprenavir can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Amprenavir.Approved
QuinidineThe metabolism of Amprenavir can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Amprenavir.Approved
RabeprazoleThe metabolism of Amprenavir can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Amprenavir.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amprenavir.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Amprenavir.Approved
RifabutinThe metabolism of Amprenavir can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Amprenavir can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Amprenavir can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amprenavir.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Amprenavir.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Amprenavir.Approved, Investigational
RitonavirThe metabolism of Amprenavir can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Amprenavir.Approved
RolapitantThe metabolism of Amprenavir can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Amprenavir.Approved, Investigational
RopiniroleThe metabolism of Amprenavir can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Amprenavir can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Amprenavir.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Amprenavir.Approved, Vet Approved
SaquinavirThe metabolism of Amprenavir can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Amprenavir can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Amprenavir.Approved
SertralineThe metabolism of Amprenavir can be decreased when combined with Sertraline.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Amprenavir.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amprenavir.Approved
SiltuximabThe serum concentration of Amprenavir can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Amprenavir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Amprenavir.Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Amprenavir.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Amprenavir.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Amprenavir.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Amprenavir.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Amprenavir.Experimental
St. John's WortThe metabolism of Amprenavir can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Amprenavir can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Amprenavir can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Amprenavir can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Amprenavir can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Amprenavir.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amprenavir.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Amprenavir.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Amprenavir.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Amprenavir.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Amprenavir.Approved
TelaprevirThe metabolism of Amprenavir can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Amprenavir can be decreased when combined with Telithromycin.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Amprenavir is combined with Temsirolimus.Approved
TerbinafineThe metabolism of Amprenavir can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Amprenavir can be decreased when combined with Teriflunomide.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Amprenavir.Approved
ThioridazineThe metabolism of Amprenavir can be decreased when combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Amprenavir.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Amprenavir.Approved
TiclopidineThe metabolism of Amprenavir can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Amprenavir.Approved
TipranavirThe serum concentration of Amprenavir can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Amprenavir can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Amprenavir can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Amprenavir.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amprenavir.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Amprenavir.Approved, Investigational
TranylcypromineThe metabolism of Amprenavir can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Amprenavir.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Amprenavir.Approved
TrimethoprimThe metabolism of Amprenavir can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Amprenavir.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Amprenavir.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Amprenavir.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Amprenavir.Approved, Investigational
ValsartanThe metabolism of Amprenavir can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Amprenavir.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Amprenavir.Approved
VenlafaxineThe metabolism of Amprenavir can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Amprenavir.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Amprenavir.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Amprenavir.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Amprenavir.Approved
VoriconazoleThe metabolism of Amprenavir can be decreased when combined with Voriconazole.Approved, Investigational
ZafirlukastThe metabolism of Amprenavir can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Amprenavir.Approved
ZiprasidoneThe metabolism of Amprenavir can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol, especially with the oral solution since it contains propylene glycol which competes with alcohol for alcohol dehydrogenase metabolism.
  • Take with or without food, however avoid lipid-rich meals.
  • Vitamin E increases amprenavir bioavailability.
References
Synthesis Reference

DrugSyn.org

US5585397
General ReferencesNot Available
External Links
ATC CodesJ05AE05
AHFS Codes
  • 08:18.08.08
PDB Entries
FDA labelDownload (120 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9132
Blood Brain Barrier-0.5886
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.7175
P-glycoprotein inhibitor IInhibitor0.7973
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8815
CYP450 2C9 substrateNon-substrate0.5
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6176
CYP450 1A2 substrateNon-inhibitor0.7641
CYP450 2C9 inhibitorNon-inhibitor0.6591
CYP450 2D6 inhibitorNon-inhibitor0.8821
CYP450 2C19 inhibitorNon-inhibitor0.6641
CYP450 3A4 inhibitorInhibitor0.6185
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7229
Ames testNon AMES toxic0.6097
CarcinogenicityNon-carcinogens0.8218
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4787 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9884
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
CapsuleOral150 mg
CapsuleOral50 mg
LiquidOral15 mg
SolutionOral15 mg/ml
Prices
Unit descriptionCostUnit
Agenerase 50 mg capsule0.65USD capsule
Agenerase 15 mg/ml Solution0.21USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5585397 No1993-12-172013-12-17Us
US6730679 No1997-11-112017-11-11Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0491 mg/mLALOGPS
logP1.85ALOGPS
logP2.43ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.61ChemAxon
pKa (Strongest Basic)2.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area131.19 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity134.08 m3·mol-1ChemAxon
Polarizability53.6 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentAminobenzenesulfonamides
Alternative Parents
Substituents
  • Phenylbutylamine
  • Aminobenzenesulfonamide
  • Sulfonylaniline
  • Amphetamine or derivatives
  • Substituted aniline
  • Aniline
  • Primary aromatic amine
  • Saccharide
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Oxolane
  • Secondary alcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary amine
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
  2. Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694 ]
  3. Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS: Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother. 1999 Jul;43(7):1686-92. [PubMed:10390223 ]
  4. Authors unspecified: Amprenavir: a new HIV protease inhibitor. Med Lett Drugs Ther. 1999 Jul 16;41(1057):64-6. [PubMed:10436772 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP: The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS. 2002 Sep 6;16(13):1743-7. [PubMed:12218384 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 02:43